Immune agents for the treatment of Devic's neuromyelitis optica

Neurological Sciences

Volumn 28, Issue 5, 2007, Pages 238-240

  Bergamaschi, Roberto ^a  

^a C MONDINO NATIONAL NEUROLOGICAL INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; BETA INTERFERON; CORTICOSTEROID; CYCLOPHOSPHAMIDE; GLATIRAMER; IMMUNOGLOBULIN; IMMUNOMODULATING AGENT; IMMUNOSUPPRESSIVE AGENT; METHYLPREDNISOLONE; MITOXANTRONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NATALIZUMAB; PREDNISONE; RITUXIMAB;

CARDIOTOXICITY; CLINICAL TRIAL; CYTOMEGALOVIRUS INFECTION; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG RESPONSE; DRUG TOLERABILITY; HEPATITIS B; HERPES ZOSTER; HUMAN; INFECTION; LEUKOENCEPHALOPATHY; MYELOID LEUKEMIA; MYELOOPTIC NEUROPATHY; NEUROPROTECTION; NOTE; PLASMAPHERESIS; RELAPSE;

HUMANS; IMMUNOLOGIC FACTORS; NEUROMYELITIS OPTICA;

EID: 35848946578     PISSN: 15901874     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10072-007-0828-7     Document Type: Note

References (18)

1. Capobianco M, Malucchi S, di Sapio A et al (2007) Variable responses to rituximab treatment in neuromyelitis optica (Devic's Disease). Neurol Sci 28:209-211
2. Bergamaschi R, Ghezzi A (2004) Devic's neuromyelitis optica: Clinical features and prognostic factors. Neurol Sci 25[Suppl 4]:S364-S367
3. Lucchinetti CF, Mandler RN, McGavern D et al (2002) A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica. Brain 125:1450-1461
4. Jarius S, Franciotta D, Bergamaschi R et al (2007) NMO-IgG in the diagnosis of neuromyelitis optica. Neurology 68:1076-1077
5. Matiello M, Jacob A, Wingerchuk DM, Weinshenker BG (2007) Neuromyelitis optica. Curr Opin Neurol 20:255-260
6. Wingerchuk DM, Hogancamp WF, O'Brien PC, Weinshenker BG (1999) The clinical course of neuromyelitis optica (Devic's syndrome). Neurology 53:1107-1114
7. Bergamaschi R, Uggetti C, Tonietti S et al (2003) A case of relapsing neuromyelitis optica treated with glatiramer acetate. J Neurol 250:359-361
8. Gartzen K, Limmroth V, Putzki N (2007) Relapsing neuromyelitis optica responsive to glatiramer acetate treatment. Eur J Neurol 14:12-13
9. Ziemssen TZ, Kuempfel T, Klinkert WEF et al (2002) Glatiramer acetate-specific T-helper 1-and 2-type cell lines produce BDNF: implications for multiple sclerosis therapy. Brain 125:2381-2391
10. Bergamaschi R (2003) Glatiramer acetate treatment in Devic's neuromyelitis optica. Brain 126:1
11. Mandler RN, Davis LE, Jeffery DR, Kornfeld M (1993) Devic's neuromyelitis optica: A clinicopathological study of 8 patients. Ann Neurol 34:162-168
12. Weinstock-Guttman B, Ramanathan M, Lincoff N et al (2006) Study of mitoxantrone for the treatment of recurrent neuromyelitis optica (Devic disease). Arch Neurol 63:957-963
13. Falcini F, Trapani S, Ricci L et al (2006) Sustained improvement of a girl affected with Devic's disease over 2 years of mycophenolate mofetil treatment. Rheumatology (Oxford) 45:913-915
14. Bakker J, Metz L (2004) Devic's neuromyelitis optica treated with intravenous gamma globulin (IVIG). Can J Neurol Sci 31:265-267
15. Cree BA, Lamb S, Morgan K et al (2005) An open label study of the effects of rituximab in neuromyelitis optica. Neurology 64:1270-1272
16. - (2007) Rituxan warning FDA Consum 41:3
17. Freim Wahl SG, Folvik MR, Torp SH (2007) Progressive multifocal leukoencephalopathy in a patient with complete remission after treatment with cytostatics and rituximab: Case report and review of the literature. Clin Neuropathol 26:68-73
18. Aksoy S, Harputluoglu H, Kilickap S et al (2007) Rituximab-related viral infections in lymphoma patients. Leuk Lymphoma 48:1307-1312